A

Aileron Therapeutics

D
ALRN
USD
-0.06
(-1.5873%)
Market Closed
252.000
Volume
-1.69
EPS
-
Div Yield
-1.200000
P/E
80,596,772.28
Market Cap
Today
-1.5873%
1 Week
-9.709%
1 Month
10.945%
6 Months
0.270%
12 Months
153.061%
Year To Date
24.832%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
A
ALRS
-0.062
(-0.2778%)
USD
A
ALRM
-0.8
(-1.3795%)
USD
A
ALKS
-0.32
(-1.0925%)
USD
A
ALG
0.51
(0.2589%)
USD
A
ALRS
-0.062
(-0.2778%)
USD
A
ALR
0
(0%)
USD
A
AL
-0.005
(-0.0106%)
USD
ALNY
ALNY
-0.795
(-0.2913%)
USD

Title:
Aileron Therapeutics

Sector:
Healthcare
Industry:
Biotechnology
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development,LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.
Do you need help or have a question?
Contact Us